Wednesday, November 9 2016
Today's Research Daily features new research reports on 16 major stocks, including Chevron (NYSE:CVX), Glaxo (GSK) and Aflac (AFL).
Chevron’s shares have gained more than 19% year-to-date. The analyst emphasizes that the company’s current oil and gas development project pipeline is among the best in the industry, boasting large, multi-year projects. Also, Chevron has been able to boost returns and remain competitive by embarking on aggressive cost reduction initiatives, exiting unprofitable markets and streamlining the organization.
Owing to these positives, the company has been able to report better-than-expected earnings in the third quarter. However, due to commodity price rout, Chevron’s upstream division has been able to extract less value for their products. (You can read the full research report on Chevron here.)
Glaxo’s shares have struggled recently. Glaxo’s third-quarter 2016 results were impressive with the company beating estimates on all fronts. The analyst likes Glaxo’s diversified base and presence in different geographical areas as well as its efforts to develop its pipeline.
The performance of new products as well as those acquired from Novartis is also encouraging. These should help support revenues and ease the impact of the loss of Advair sales. However, challenges remain in the form of increasing competition, genericization and pricing pressure, which will continue to impact the company’s performance. (You can read the full research report on Glaxo here.)
Aflac’s shares have increased by more than 8% year-to-date. Aflac’s third quarter earnings exceeded expectations and grew year over year. The analyst likes the way in which company is trying to differentiate itself from its rivals by paying claims in one day through a program named “One Day Pay.” Aflac’s strong capital position enables it to buy back shares and increase dividend payouts at regular intervals.
Efforts to increase agent productivity also will drive long-term growth. However, Aflac’s top line remains exposed to a challenging operating environment, primarily in Japan. (You can read the full research report on Aflac here.)
Other noteworthy reports we are featuring today include Analog Devices (ADI), Novo Nordisk (CO:NOVOb) (NVO) and MGM Resorts (MGM).
Confidential: Best Trades from Zacks Research
Would you like to see a hand-picked "all-star" selection of investment ideas from the man who heads up Zacks' trading and investing services? Steve Reitmeister knows when key trades are about to be triggered and which of our experts has the hottest hand. He is now prepared to pass them along to you. From 220 Zacks Rank #1 Strong Buys, this Special tabs 7 for immediate breakout. Click to access these private picks>>
Mark Vickery
Senior Editor
Note: If you want an email notification each time Sheraz publishes a new article, please click here>>>
Today's Must Read
Featured Reports
Novo Nordisk (NVO) Diabetes Drugs Drive Sales in Q3
The Zacks analyst believes that strong performance of drugs like Victoza, Tresiba and Saxenda should continue driving sales in future quarters.
TELUS Corp. (TU) to Benefit from IoT Plans & New Tie-Ups
The covering analyst believes that TELUS is actively pursuing new deals and alliances and aims to consolidate its foothold in the Internet of Things (IoT) market.
Stanley Black (SWK) Beats Q3 Earnings, View Up Despite Woes
Stanley Black & Decker (NYSE:SWK) has solid long-term growth potential and it beat the earnings estimate for third-quarter 2016. It raised its earnings guidance for 2016 despite headwind risks in the near term.
Parker-Hannifin (NYSE:PH) Q1 Earnings Beat; Prospects Bright
The Zacks analyst thinks stabilization in end markets and savings from realignment actions bode well for growth.
Analog Devices (ADI) Hurt by Weakness in the Consumer Market
The covering analyst believes that Analog Devices' strength in the industrial, auto and communication markets is largely offset by significant weakness in the consumer business.
Fifth Third's (FITB) Q3 Results Depict Revenue Strength
The Zacks analyst remains optimistic as Fifth Third recorded higher revenues and sustained loan and deposit growth in Q3.
Ventas (VTR) to Gain from SNF Biz Curb, Rate Hike Woes Linger
The covering analyst believes Ventas is likely to benefit from efforts to curb skilled nursing facilities business.
New Upgrades
MGM Resorts (MGM) Poised for Growth Post Q3 Earnings
The Zacks analyst is upbeat about MGM Resorts post its Q3 earnings results. Strong portfolio, focus on non-gaming actions, with improving economy and budding tourism in Las Vegas should drive growth.
Xcel Energy (NYSE:XEL) Beats on Earnings in Q2, Narrows View
The covering analyst believes that Xcel Energy's future performance is likely to improve with improving economic conditions across its service territories.
Ingersoll (IR) Beats Q3 Earnings on Healthy Growth Dynamics
Ingersoll reported strong 3Q16 results with year-over-year increase in both earnings and revenues that beat the respective Zacks Consensus Estimates.
New Downgrades
Symantec's (NASDAQ:SYMC) Tepid View Overshadows Modest Q2 Results
Tepid third quarter revenue guidance makes the Zacks analyst increasingly cautious about its near-term performance.
Kimco (KIM) at Risk with Asset Sales, Tenant Bankruptcies
The covering analyst thinks earnings dilution led by high disposition activity, tenant bankruptcy and competition from other players are causes of concern.
Navistar (NAV) to be Hit by Weak Deliveries in US, Canada
Economic uncertainties in Brazil are negatively impacting Navistar's results. Weak delivery guidance for the U.S. and Canada and lower revenues guidance for the year also pose concerns.
NOVO-NORDISK AS (NVO): Free Stock Analysis Report
MGM RESORTS INT (MGM): Free Stock Analysis Report
GLAXOSMITHKLINE (GSK): Free Stock Analysis Report
CHEVRON CORP (CVX): Free Stock Analysis Report
AFLAC INC (AFL): Free Stock Analysis Report
ANALOG DEVICES (ADI): Free Stock Analysis Report
Original post
Zacks Investment Research